Home
Life Science Investing Biotech Investing

Canadian Investment Regulatory Organization Trade Resumption - CRDL

Investing News Network

October 20, 2025

Trading resumes in:

Company: Cardiol Therapeutics Inc.

TSX Symbol: CRDL

All Issues: Yes

Resumption (ET): 8:00 AM

CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada..

SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

View original content: http://www.newswire.ca/en/releases/archive/October2025/20/c1710.html

News Provided by Canada Newswire via QuoteMedia

CRDL:CA

Alert Options

No alert set

INN Article Notification

Instant Daily Weekly

Alert Option

You will be notified when this event occurs. No additional settings needed.

The Conversation (0)

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Investing News Network

09 September

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the... Keep Reading...

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Investing News Network

08 September

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to... Keep Reading...

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Investing News Network

04 September

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September... Keep Reading...

Investing News Network

01 September

BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation

Clinical-stage immuno-oncology company BriaCell Therapeutics (TSX:BCT,NASDAQ:BCTX) has achieved a “key genetic engineering milestone” with ‘Melanoma’, its personalized whole-cell melanoma immunotherapy vaccine candidate.The achievement allows the vaccine’s program to proceed towards clinical... Keep Reading...

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Investing News Network

01 September

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received... Keep Reading...

DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Investing News Network

24 August

DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0... Keep Reading...